{
    "2018-02-08": [
        [
            {
                "time": "",
                "original_text": "中国：医疗保健：国家食药监局优先审评令新产品周期加速",
                "features": {
                    "keywords": [
                        "国家食药监局",
                        "优先审评",
                        "新产品周期",
                        "加速"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗保健"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "[推荐评级]医药生物行业深度研究：以AVASTIN为例看国内外贝伐珠单抗市场-创新药“工具书”系列之单抗(VEGF靶点)",
                "features": {
                    "keywords": [
                        "医药生物",
                        "AVASTIN",
                        "贝伐珠单抗",
                        "创新药",
                        "VEGF靶点"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[强于大市评级]医药生物行业专题研究：500亿的PD-1/L1抗体市场空间是如何量化测算的",
                "features": {
                    "keywords": [
                        "医药生物",
                        "PD-1/L1抗体",
                        "市场空间",
                        "量化测算"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "独家：微医完成四大业务整合或为IPO铺路 未来不排除分拆上市",
                "features": {
                    "keywords": [
                        "微医",
                        "业务整合",
                        "IPO",
                        "分拆上市"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "恒指高开低走涨0.06% 权重股走弱",
                "features": {
                    "keywords": [
                        "恒指",
                        "高开低走",
                        "权重股",
                        "走弱"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "指数"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "国企民企携手 进得来、干得好、退得出",
                "features": {
                    "keywords": [
                        "国企",
                        "民企",
                        "携手合作"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "国企民企合作"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}